Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Monopar Therapeutics

Get SEC filing alerts via email and in your feed for Monopar Therapeutics

MNPR

Monopar Therapeutics

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharma company developing treatments for Wilson disease and radiopharmaceuticals for oncology. Its pipeline includes ALXN1840, an investigational oral drug for Wilson disease, and targeted radiopharmaceuticals like MNPR-101 for cancer imaging and therapy. The company leverages licensing, in-house research, and collaborations to advance precision medicines targeting tumors and rare genetic disorders globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Monopar Therapeutics

1
1
Monopar Therapeutics Monopar Therapeutics Reports $3.9 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Monopar Therapeutics Monopar Therapeutics Reports $13.7 Million Net Loss, Advances Product Pipeline

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Monopar Therapeutics Monopar Therapeutics Reports Increased Losses and Cash Surge in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Monopar Therapeutics Monopar Therapeutics Reports $2.5 Million Net Loss in Q2 2025, Increases R&D and G&A Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Monopar Therapeutics Monopar Therapeutics Reports $2.6 Million Net Loss in Q1 2025, Increases R&D and G&A Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Monopar Therapeutics Monopar Therapeutics Reports Increased Net Loss and Significant Liquidity Growth in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Monopar Therapeutics Monopar Therapeutics Reports Continued Losses, Strategic Developments Amid Ongoing Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments